Breaking News

Eidos Therapeutics files for initial public offering

Eidos Therapeutics Inc. eidx plans to release an preliminary public providing, according to a Securities and Exchange Commission submitting overdue Friday. The Palo Alto, Calif.-based biotech drug developer stated it plans to raise as much as $115 million, even though amounts listed in preliminary filings are in most cases placeholders which might be revised in later filings. Eidos stated it plans to use 80% of proceeds to lend a hand fund clinical trials for its drug candidate AG10 for the treatment of transthyretin amyloidosis, a situation the place protein deposits construct round organs and reason harm. J.P. Morgan, Bank of America Merrill Lynch and Barclays are listed a few of the underwriters. The corporate has already raised $64 million in venture capital investment, according to Crunchbase. The corporate, which has but to supply earnings, reported a lack of $11.nine million in 2017, and a lack of $15.6 million in the quarter ended March 31, 2018. Eidos plans to listing under the ticker "EIDX" on the Nasdaq.